Great f.y.i. Get hooked here!
Long-Term Findings From EORTC1325/KEYNOTE-054 Show Adjuvant KEYTRUDA Demonstrated a Sustained Recurrence-Free Survival Benefit Versus Placebo Across Stage IIIA (>1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma Merck Is Advancing a Broad Clinical Program Evaluating KEYTRUDA for the Early Treatment of Cancer
HOBOKEN, N.J.–(BUSINESS WIRE)–It is with great sadness that John Wiley & Sons, Inc. announces the death of Board Member William (Bill) Pence, who passed earlier this month. “Bill was a trusted advisor and a champion of transformation, from culture to tech driven
A public scolding of the C.D.C. chief was only the latest but perhaps the starkest instance when the president has rejected not just the policy advice of his public health officials but the facts and information that they provided. — NYT:
Leading behavioral care provider also introduces nationwide availability of new mental health coaching services and expands therapy offering to 10 states MINNETONKA, Minn.–(BUSINESS WIRE)–Sanvello Health, Inc., a leading digital mental health care provider and a UnitedHealth Group (NYSE: UNH) company, today announced
Companies will partner to develop novel antibody-drug conjugates using Catalent’s SMARTag bioconjugation platform and monoclonal antibodies from Exelixis’ growing preclinical pipeline Agreement includes exclusive options on multiple targets over three-year term, with potential to extend time and scope of the collaboration Deal
SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported financial results for the quarter ended June 30, 2020. “Legend Biotech
Company Introduces Tool for Measuring and Monitoring Axial Length Metrics OAKLAND, N.J.–(BUSINESS WIRE)–#SeeingEyeHealthDifferently–Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it has launched its new Aladdin-M instrument to the US
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine®
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #AML—Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or